Cheyenne Wells

Researchers are investigating multi-cancer detection (MCD) tests as a new way to screen for multiple cancers at once in adults aged 45 to 75 without cancer. This study is a feasibility trial called the Vanguard Study designed to explore how well these MCD tests work as cancer screening tools and to understand how patients and doctors decide on care based on the test results. The study will compare two different MCD tests to a control group, aiming to provide early information on their performance and impact. Participants are randomly assigned to one of three groups: one group will have blood collected for the Shield MCD test, another for the Avantect MCD test, and a control group will have blood collected without MCD testing. Blood samples are collected at enrollment and again after one year. Some sites will share test results with participants, while others will keep results blinded. After the intervention period, participants will be followed passively for up to 10 years. During the study, participants complete baseline and follow-up questionnaires within 60 days, provide blood samples for MCD testing within 90 days, and allow researchers to collect health data from medical records. The study measures enrollment feasibility, follow-up completion, diagnostic resolution of abnormal results, test accuracy, and participant anxiety related to the testing process. Safety and long-term outcomes such as cancer incidence and mortality are also monitored throughout the study period.